|
|
News Breaks
|
October 28, 2009
|
| 17:03 EDT |  | CRME |
| theflyonthewall.com: | Cardiome Pharma and Astellas initiate patient enrolment for ACT 5 trial | | Cardiome Pharma and its co-development partner Astellas Pharma announced that patient enrolment has begun for the ACT 5 trial, a confirmatory Phase 3 clinical trial of KYNAPID, or vernakalant hydrochloride, Injection, a drug product candidate under development for the rapid conversion of atrial fibrillation to sinus rhythm. The ACT 5 trial, previously announced in August 2009, is expected to be completed in the first half of 2011. :theflyonthewall.com |
|
|
News For CRME From The Last 14 Days Check below for free stories on CRME the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
